Clearmind Medicine sets USD 1 conversion price for USD 696,079.50 in notes into common shares

• Clearmind set a $1 per-share conversion price for outstanding convertible notes totaling USD 696,079.50, overriding the notes’ conversion formula.
• The notes were originally issued under a September 17, 2025 securities purchase agreement, later amended on April 30, 2026.
• The conversion will be settled in common shares equal to the converted amount divided by $1, rounded under the notes’ terms.
• The company amended the notes’ Floor Price definition to $1 for this conversion.
• The conversion shares are registered for resale under an effective SEC registration statement, with issuance required without restrictive legends.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-096692), on September 02, 2026, and is solely responsible for the information contained therein.